The most important adverse reactions of cytarabine are myelosuppression, gastrointestinal reactions, and hepatic impairment. 1. Myelosuppression: mainly manifested as macrocytosis, leukopenia, anemia, reticulocytopenia and thrombocytopenia. The incidence and severity of myelosuppression after a single application of cytarabine is very low, but almost all patients receiving daily or continuous intravenous infusion of cytarabine will develop myelosuppression. 2. Gastrointestinal reactions: Nausea and vomiting are common, with a higher incidence with rapid intravenous infusion, as well as anorexia, diarrhea, abdominal pain, esophageal ulceration, and gastrointestinal bleeding. 3. Hepatic impairment: jaundice, elevated serum bilirubin, aminotransferase and alkaline phosphatase can occur. 4. Other adverse reactions to cytarabine include fever, rash, conjunctivitis, alopecia, skin blotchiness, skin ulcers, urinary retention, renal impairment, chest pain, dizziness, somnolence, and neuritis. The use of cytarabine should be in accordance with medical advice.